Edison Pharmaceuticals, Inc. Licenses Drug from Centocor, Inc. (JNJ) for Rare Diseases  
1/5/2010 10:39:27 AM

MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has licensed CNTO-530, a clinical-stage compound discovered and developed by Centocor R&D, Inc. for clinical evaluation in rare mitochondrial and other neglected diseases. The terms of the transaction have not been disclosed.

Edison Pharmaceuticals, Inc.